Chrystal Paulos
@Chrystal_Paulos
Followers
3K
Following
7K
Media
724
Statuses
3K
Director of Translational Research, Cutaneous Malignancies | Prof. in Surgery & M+I Dept | @EmoryUniversity @EmorySurgery @WinshipAtEmory @Pauloslab
Atlanta, Ga
Joined June 2010
RT @may_daher: Beautiful work that can be applied to enhance the field of immunometabolism! Congratulations @thalexandrov and team! #metabo….
0
1
0
RT @PatrickHwuMD: #FollowFriday Dr. Jeff Rathmell is Chair of the Ben May Department for Cancer Research and Director of the Ludwig Center….
0
1
0
RT @jitcancer: New #JITC position article and guidelines: Constructing the cure: engineering the next wave of antibody and cellular immune….
0
9
0
RT @Zihai: This is our preclinical work on targeting TGFβ docking receptor GARP via CAR-T cell platform to treat #glioblastoma Our clinical….
academic.oup.com
AbstractBackground. Glycoprotein A-repetitions predominant (GARP) is a cell surface non-signaling receptor for docking and activating latent transforming g
0
7
0
RT @PatrickHwuMD: #ScienceSaturday. ❓ Why do some patients respond better to immunotherapy?. ➡️ A new study in Nature found that tumors wit….
0
45
0
RT @jitcancer: New #JITC article: Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healt….
0
7
0
RT @jitcancer: New #JITC article: An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited….
0
6
0
RT @sitcancer: Read the fifth and final manuscript, "Constructing the Cure: Engineering the Next Wave of Antibody and Cellular Immune Thera….
0
2
0
@StefanieBailey_ @ChrisHeery @LesinskiLab @megen_wittling @PaulosLab @IAmDrDex 10 and Final: Check out the full paper here: Join the conversation. Let’s build the future of cancer immunotherapy, together.
jitc.bmj.com
Immuno-oncology has revolutionized cancer treatment by mobilizing the immune system to eliminate tumors. Although immune checkpoint inhibitors and T cell therapies have mediated durable responses in...
1
0
2
9: A huge thank you to this powerhouse team #TeamScience :.@StefanieBailey_ @chrisheery @LesinskiLab @megen_wittling @PaulosLab @IAMDrDex.EricBartee, KyleDaniels, PravinKaumaya, TimLowinger, MichelleNelson, MarkRubinstein.Collaborations build IO future.
1
0
2
8: The future is about integration and access:.Rational combinations.Equitable, diverse trials.Scalable tech to bring next-gen IO everywhere.
1
0
0
7: AI and ML are supercharging IO:.🔍 Identifying novel targets.⚙ Optimizing manufacturing.🧠 Predicting responses & resistance.💡 Designing smarter constructs faster.📊 Figure 5: AI-driven IO innovation
1
1
0
6: Innovation isn’t stopping at T cells. Engineered NK cells, macrophages, and even B cells are gaining traction, each offering unique tools to outsmart tumors. 📊 Figure 4 works perfectly here too (see above tweet).
1
0
1
5: FDA approve T cell therapies & new armored CAR T cells are no longer theoretical. From cytokine secretion to logic-gated circuits, these cells are being built to:.⚔ Thrive in solid tumors.⚖ Reduce systemic toxicity.📊 Figure 4: Overview of ACT platforms
4
1
3
4: The future of IO hinges on smart design:.✔ Enhancing tumor specificity.✔ Overcoming suppressive TMEs.✔ Improving persistence & safety.✔ Scaling for global access.📊 Figure 3: Mechanisms of bispecific antibodies
1
1
3